There is no evidence that COVID-19 vaccines increase the incidence of Guillain-Barré syndrome, a study finds.
Published in the journal Vaccine, a statistical analysis finds that there was not a significant association between any of the COVID-19 vaccinations currently offered and the disease, a rare neurological disorder in which the body’s immune system attacks the nerves.
In July 2021, the US Food and Drug Administration issued a warning, based on early reports, that those receiving the Johnson & Johnson’s COVID-19 vaccine may be at a greater risk of developing the sometimes-fatal disease.
Researchers developed an artificial intelligence tool that aided their analysis and drew information from the Vaccine Adverse Event Reporting System (VAERS). The national database, which includes reports on harmful effects from vaccines that can be filed by physicians or patients, is maintained by the FDA and the US Centers for Disease Control and Prevention.
“This is important because we can say that there is no significant increased risk of Guillain-Barré syndrome in the population, using VAERS data,” says Mustafa Jaffry, a medical student at Rutgers New Jersey Medical School and the first author of the study. “This information can help in ensuring confidence in vaccines, while approaching it from an objective, statistical analysis.”
After learning of the initial warning, the researchers wanted to dig more deeply to understand whether the risk, even if minimal, for developing the syndrome was real. They also wanted to look at all brands of COVID-19 vaccines as well as reports on other types of vaccines because there has long been a suggestion of an association between vaccines and the syndrome. The thinking, Jaffry says, is that there may be some connection, since vaccinations stimulate the immune system, and the syndrome is an immune system disorder.
“It’s a burning question in medicine,” Jaffry says.
Guillain-Barré syndrome is often caused by a bacterial infection, compounding the difficulty in conducting an analysis.
“The original reports were just saying that someone got vaccinated, and then a few weeks later, developed Guillain-Barré syndrome,” Jaffry says. “But they could have had an infection at that time that was unrelated to the vaccine.”
To ascertain whether there was a statistically significant increase in the disease among those vaccinated, the team collected vaccine data from the VAERS database and organized it in several ways. First, they divided the data into three time periods, using the time before the emergence of COVID-19 and the interval before the advent of vaccines as “control” periods offering comparison of disease rates to the third time span, which started with the introduction of the vaccine. They calculated how many vaccines were administered in each time period. They also included in their analysis adverse reports on vaccines for influenza, HPV, meningitis, and pneumococcal pneumonia. In addition, they assigned a value to each case of reported Guillain-Barré syndrome indicating the likelihood it represented a true diagnosis of the syndrome.
“The primary observation is that we found that while there were more reports of Guillain-Barré syndrome after COVID-19 vaccines compared to other vaccines, this rate was not higher than the incidence of Guillain-Barré syndrome in the general population,” says study leader Nizar Souayah, professor of neurology and the corresponding author of the study. “The significance of that statement is this: The COVID vaccine is not statistically associated with an increased risk of Guillain-Barré syndrome.”
The researchers plan to continue to employ their newly devised analytical methods to explore other possible associations between vaccines and diseases.
Additional researchers contributed from Rutgers; New Jersey Pediatric Neuroscience Institute in Morristown, NJ, Columbia University in New York; Northeastern University in Boston; and Texas Tech University in Lubbock, Texas.
Source: Kitta MacPherson for Rutgers University
